|  |
| --- |
| September 12, 2016 |
|  |
| Tim Lange  Head of Investor Relations  Phone +49 201 177-3150  tim.lange@evonik.com |
|  |
| Evonik Industries AG  Rellinghauser Straße 1-11  45128 Essen Germany  Phone +49 201 177-01  Telefax +49 201 177-3475  www.evonik.com  **Supervisory Board**  Dr. Werner Müller, Chairman  Executive Board  Dr. Klaus Engel, Chairman  Christian Kullmann, Deputy Chairman  Dr. Ralph Sven Kaufmann Thomas Wessel  Ute Wolf  Registered office Essen  Registered court  Essen local court  Commercial registry B 19474  VAT ID no. DE 811160003 |

**Evonik reduces production capacity for superabsorbents**

Essen. Evonik recently reduced production capacity for superabsorbents by 40,000 metric tons to 530,000 meric tons per year. The production lines concerned are those at the Garyville and Greensboro (North Carolina, USA) sites, two of Evonik’s five superabsorbents production sites worldwide.

“With this measure we’re adapting to demand trends. We plan to take the opportunity to bring capacity to the technological state of the art and to start up the lines again in 1 – 2 years,” says Norbert Westerholt, head of the Baby Care Business Line at Evonik.

Evonik is pursuing the goal of remaining a reliable, competitive, and innovative partner of superabsorbents customers over the long term.

As one of the leading suppliers of superabsorbents, Evonik is established as a reliable, innovative and long-term partner in the superabsorbents industry.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders   
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around   
€4.9 billion in 2015

**Disclaimer**

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.